

MEDICAL ONCOLOGY**PAPER-II**Time: 3 hours
Max. Marks:100

MED ONCO/J/19/17/II

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Causes of malignant spinal cord compression (MSCC). 3+3+4
b) Grading the MSCC.
c) Management of MSCC.
2. a) Gene expression profile. 2+4+4
b) What are the tests available for breast cancer gene expression profile?
c) Use of gene expression profile results in breast cancer management.
3. a) Staging of non-small cell lung cancer (NSCLC) 4+3+3
according to 8th Edition Lung Cancer Stage Classification.
b) Role of mutation analysis in treatment of NSCLC.
c) Consolidation treatment after definitive concurrent chemo-radiation in stage III NSCLC.
4. a) Role of PET CT scan in lymphomas. 4+3+3
b) Limitations of PET CT use in clinical practice.
c) PET response adopted treatment in Hodgkin's lymphoma.
5. a) WHO Classification of neuroendocrine tumours of 3+4+3
pancreas.
b) Management of advanced pancreatic neuroendocrine tumours.
c) Peptide receptor radiotherapy.
6. a) Gleason grading in adenocarcinoma prostate. 3+3+4
b) Role of PSA in screening and follow up of prostate cancer.
c) Enumerate anti-androgen therapies in carcinoma prostate.

P.T.O.

MEDICAL ONCOLOGY**PAPER-II**

- | | | |
|-----|---|-------|
| 7. | a) Role of cytoreductive nephrectomy in metastatic renal cell carcinoma. | 3+4+3 |
| | b) Role of adjuvant treatment in clear cell renal cell carcinoma. | |
| | c) Risk scoring systems and their use in metastatic renal cell carcinoma. | |
| 8. | a) Explain the methodology of Real time polymerase chain reaction (RT PCR). | 3+4+3 |
| | b) Monitoring of response in CML treatment | |
| | c) Criteria for accelerated phase and blast crisis in CML. | |
| 9. | a) Etiological factors of Hepatocellular Carcinoma (HCC). | 3+4+3 |
| | b) Diagnosis and staging of HCC. | |
| | c) Indications of allogenic liver transplantation in HCC. | |
| 10. | a) Enumerate various types of neck dissections in squamous cell carcinoma of head and neck. | 3+4+3 |
| | b) Role of neo-adjuvant chemotherapy in oro-pharyngeal cancer. | |
| | c) Rehabilitation after laryngectomy. | |
